Adenosine
Brand Names: Tissen NF 10, Tissen Icm 10, Reorganic Feminine Wash, The Skinhouse Green Tea Collagen, Sferangs Collagen Recharging Toner, The Skinhouse Wrinkle Collagen Free Spot
Methodology & AI Transparency ⓘ
Adenosine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Intravenous adenosine injection is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).
- 2 Real-world patient consensus: Real-world cohort score of 91% across 14 de-identified Adenosine entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $89.91 cash mean against $220.28 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Adenosine tolerability events: headache (2%), dizziness (1%), orthostatic hypotension (1%).
Ask our AI Specialists anything about Adenosine
Adenosine Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Intravenous adenosine injection is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine injection solution actually reaches the systemic circulation . Adenosine injection does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.
Mechanism of Action Adenosine injection slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome. Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.
Systemic exposure to Adenosine reflects Complete (~100%) parenteral systemic delivery for Adenosine (3 mg/mL Injection) absorption kinetics and systemic clearance of adenosine integrates hepatic phase ii conjugation with renal filtration, sustaining receptor engagement across a Elimination kinetics span 5 to 16 hours per Adenosine clinical pharmacology half-life window (rapid intravascular/parenteral onset within 15–45 minutes after adenosine administration response profile).
Dosing protocols (3 mg/mL Injection or .04 g/100mL Liquid or .01 g/30mL Cream or .005 g/13mL Liquid or .04 g/100mL Cream) balance efficacy (91.00% patient satisfaction across 14 logs) against nausea (9.2% of reports), palpitations (4.6% of reports), blurred vision (4.2% of reports), with strict avoidance in contraindications intravenous adenosine injection is contraindicated in: second- or third-degree a-v block (except in patients with a functioning artificial pacemaker).; sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).; known hypersensitivity to adenosine..
Transporter-mediated clearance of P-gp substrates may slow during concurrent Adenosine administration.
Staggering Adenosine apart from antacid or iron products prevents insoluble gastrointestinal complexation.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Intravenous adenosine injection is contraindicated in: Second- or third-degree A-V block (except in patients with a functioning artificial pacemaker).
- Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker).
- Known hypersensitivity to adenosine.
Logged Side-Effect Incidence (14 Reports)
Adenosine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Adenosine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of piclidenoson in plaque psoriasis skin flare-ups: Results: What a 529-Participant Study Found Piclidenoson demonstrated efficacy responses that increased over time alongside a favourable safety profile. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-06-15 • Phase III Randomized Trial | N = 529 | 93/100 | PMID 38279575 ↗ |
| Can This Approach Help? Inside the Latest Research on Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment The similar rate of emerging Nsp12 substitutions in the remdesivir and placebo arms and the minimal change in remdesivir susceptibility among tested substitutions support a high barrier to remdesivir resistance development in... The Journal of infectious diseases • 2023-11-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37466213 ↗ |
| Can This Approach Help? Inside the Latest Research on Skin-applied adenosine increases the proportion of thick hair in Caucasian men No adverse effects due to treatment were noted during this study by dermatological evaluation. The Journal of dermatology • 2016-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 26508659 ↗ |
| Can This Approach Help? Inside the Latest Research on Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired Three of the four participants had undergone SOT. Antimicrobial agents and chemotherapy • 2026-08-05 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42429789 ↗ |
| Can This Approach Help? Inside the Latest Research on SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir None of the emergent substitutions in Nsp8, Nsp10, Nsp13, or Nsp14 (remdesivir, 10/115 [8.7%]; placebo, 10/129 [7.8%]) showed reduced remdesivir susceptibility. Antimicrobial agents and chemotherapy • 2025-02-13 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39699245 ↗ |
Adenosine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.0100/unit (~$60.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $220.28 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $89.91 / mo | View logs ↓ |
Adenosine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Adenosine RxNorm Concept ID | 1654169 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.0100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $220.28 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $89.91 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Adenosine Patient Community, Cohort Filters & Dosage Logs
Cross-verified Adenosine (adenosine receptor agonist) monograph synthesizing RxNorm 1654169, openFDA FAERS signals, and $89.91–$220.28 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Adenosine community threads and patient logs by age, biological sex, dosage, and treatment duration.